Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 14, 2019 - Issue
Submit an article Journal homepage
59
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies

Jill A Ohar1 Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA, [email protected]Correspondence[email protected]
,
Alyssa Bowling2 Sunovion Pharmaceuticals Inc, Marlborough, MA, USA
,
Thomas Goodin2 Sunovion Pharmaceuticals Inc, Marlborough, MA, USA
,
Barry Price2 Sunovion Pharmaceuticals Inc, Marlborough, MA, USA
,
Ayca Ozol-Godfrey2 Sunovion Pharmaceuticals Inc, Marlborough, MA, USA
,
Sanjay Sharma2 Sunovion Pharmaceuticals Inc, Marlborough, MA, USA
&
Shahin Sanjar2 Sunovion Pharmaceuticals Inc, Marlborough, MA, USA
 show all
Pages 461-470 | Published online: 19 Feb 2019

References

  • Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global strategy for the diagnosis, management and prevention of COPD2018 Available from: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdfAccessed May 15, 2018
  • CalverleyPMABurgePSSpencerSAndersonJAJonesPWBronchodilator reversibility testing in chronic obstructive pulmonary diseaseThorax200358865966412885978
  • HananiaNACelliBRDonohueJFMartinUJBronchodilator reversibility in COPDChest201114041055106321972384
  • RoglianiPOraJPuxedduECazzolaMAirflow obstruction: is it asthma or is it COPD?Int J Chron Obstruct Pulmon Dis2016113007301327942210
  • TashkinDKestenSLong-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responsesChest200312351441144912740259
  • TashkinDPCelliBDecramerMBronchodilator responsiveness in patients with COPDEur Respir J200831474275018256071
  • PellegrinoRViegiGBrusascoVInterpretative strategies for lung function testsEur Respir J200526594896816264058
  • Seebri Neohaler [prescribing information]Marlborough, MASunovion Pharmaceuticals Inc2018
  • PongCKGlycopyrrolate (Seebri Neohaler) for maintenance therapy in patients with COPDAm Fam Physician201796639539828925636
  • KerwinESilerTMKorenblatPEfficacy and safety of twice-daily glycopyrrolate versus placebo in patients with COPD: the GEM2 studyChronic Obstr Pulm Dis20163254955928848879
  • LaforceCFeldmanGSpangenthalSEfficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 studyInt J Chron Obstruct Pulmon Dis2016111233124327354782
  • JonesPWSt. George’s respiratory questionnaire: MCIDCOPD200521757917136966
  • MahlerDAWitekTJThe MCID of the transition dyspnea index is a total score of one unitCOPD2005219910317136969
  • DonohueJFJonesPWBartelsCCorrelations between FEV1 and patient-reported outcomes: a pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary diseasePulm Pharmacol Ther201849111929277690
  • van BuulARKasteleynMJChavannesNHTaubeCMorning symptoms in COPD: a treatable yet often overlooked factorExpert Rev Respir Med201711431132228282500
  • RocheNChavannesNHMiravitllesMCOPD symptoms in the morning: impact, evaluation and managementRespir Res20131411224143997
  • DingBSmallMBergströmGHolmgrenUA cross-sectional survey of night-time symptoms and impact of sleep disturbance on symptoms and health status in patients with COPDInt J Chron Obstruct Pulmon Dis20171258959928243077
  • VestboJHurdSSAgustíAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.